news

news and events

The Translational Landscape of Reactive Astrocytes Reveals the Impact of eIF2B-mediated Dysregulation in VWM Disease

Research / April 9, 2025

Understanding Vanishing White Matter Disease Through Astrocyte Translation Regulation This study investigates the molecular underpinnings of Vanishing White Matter Disease (VWMD), a severe, inherited neurodegenerative disorder caused by mutations in the eIF2B complex, a critical regulator of mRNA translation and the integrated stress response. VWMD primarily affects astrocytes, the brain’s support cells, yet the specific …

The Translational Landscape of Reactive Astrocytes Reveals the Impact of eIF2B-mediated Dysregulation in VWM Disease Read More »

ALEXANDER DISEASE CAREGIVER Information

News / March 11, 2025

Just Worldwide is conducting a market research study on behalf of a pharmaceutical company. The study aims to gather insights from caregivers of people with Alexander Disease to better understand their experiences and opinions. The research involves a 40-minute online survey. Participants who complete the survey will receive $100 as compensation for their time. If …

ALEXANDER DISEASE CAREGIVER Information Read More »

The ULF Board of Directors’ statement regarding the changes to healthcare and research because of reduced NIH funding.

News / February 24, 2025

The United Leukodystrophy Foundation Board of Directors’ statement regarding the changes to healthcare and research because of reduced NIH funding. February 24, 2025 “The United Leukodystrophy Foundation (ULF) is deeply concerned about proposed changes in healthcare and research. These changes may limit patient access to life-saving treatments; may impact the ability of physicians and other …

The ULF Board of Directors’ statement regarding the changes to healthcare and research because of reduced NIH funding. Read More »

FDA Approves First Treatment for CTX, a Rare Lipid Storage Disease

News, Research / February 21, 2025

PRESS RELEASE: FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease The U.S. Food and Drug Administration (FDA) has approved Ctexli (chenodiol) as the first treatment for cerebrotendinous xanthomatosis (CTX), a rare lipid storage disorder. CTX is a genetic condition caused by mutations in the CYP27A1 gene, leading to improper cholesterol breakdown …

FDA Approves First Treatment for CTX, a Rare Lipid Storage Disease Read More »

Experiences of mothers of long-term surviving patients with cerebral adrenoleukodystrophy: a qualitative study

Research / November 25, 2024

Experiences of mothers of long-term surviving patients with cerebral adrenoleukodystrophy: a qualitative study Overview: The study focuses on the lived experiences of mothers caring for long-term survivors of cerebral adrenoleukodystrophy (CALD), a rare genetic disorder affecting the nervous system. It employs qualitative research methods, including in-depth interviews with mothers, to gather rich, personal insights. Key …

Experiences of mothers of long-term surviving patients with cerebral adrenoleukodystrophy: a qualitative study Read More »

PMD Clinical Study

Clinical Trials / November 25, 2024

Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD) Study Overview Brief Summary The primary purpose of this study is to evaluate the safety and tolerability of ION356. Detailed Description This is a Phase 1b, open-label multiple-ascending dose (MAD) study of ION356 …

PMD Clinical Study Read More »

Aspa Therapeutics: A Study of AAV9 Gene Therapy in Children With Canavan Disease

Clinical Trials / November 25, 2024

Aspa Therapeutics: A Study of AAV9 Gene Therapy in Children With Canavan Disease (CANaspire Clinical Trial) [https://treatcanavan.com/canaspire-trial/]   Aspa’s investigational gene therapy trial uses an AAV9 vector (adeno-associated virus serotype 9), which is designed to deliver functional copies of the ASPA gene throughout the body, including into the brain, to address the underlying cause of Canavan disease. The AAV9 …

Aspa Therapeutics: A Study of AAV9 Gene Therapy in Children With Canavan Disease Read More »

Aspa Therapeutics: A Natural History Study of Patients With Canavan Disease

News / September 24, 2024

Aspa Therapeutics: A Natural History Study of Patients With Canavan Disease (CANinform Study) [https://clinicaltrials.gov/study/NCT04126005] CANinform is a natural history study of patients with Canavan disease that will help researchers better understand the disease and provide a foundation for Aspa’s gene therapy program. The study is open to individuals with a confirmed diagnosis of Canavan disease.